ALK and non-small cell lung carcinoma: In this study, to understand the lorlatinib-tolerant and lorlatinib-resistant mechanisms and investigate therapeutic strategies to overcome lorlatinib persistence/resistance in ALK-positive NSCLC, we tried to establish lorlatinib tolerant persister cells with the intermittent lorlatinib treatment repeated 3 times, and succeeded to establish lorlatinib intermediate resistant cells and explored the mechanisms and effective inhibitors to eliminate them.